LidexaGel 5%

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
LidexaGel 5%
Generic name
LIDOCAINE HCL
Manufacturer
Oncora Pharma, LLC
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
b45a7d2f-111f-4390-9b90-570b1c9f5ffc
SPL ID
3899614e-a1ed-4642-937b-5d8e55a81c9a
Version
1
Effective date
2026-07-08
Source export date
2026-11-13
Source partition
10
Source file
https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:14:32
Harmonized routes table
Harmonized routes
TOPICAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 2 matching rows.

warnings and cautions

WARNINGS: For external use only. Not for ophthalmic use.

warnings and cautions

PRECAUTIONS: If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy. LidavexGel 5% should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of lidocaine.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS: During or immediately after treatment, the skin at the site of treatment may develop erythema or edema or may be the locus of abnormal sensation.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.